Novo Nordisk argues Medicare should negotiate the price for six of its insulin products separately, though they contain the ...

The complete response letter (CRL) specifies that the current dosage duration of aflibercept is still safe but extending the ...

Dupixent, which was rejected by the FDA for chronic spontaneous urticaria in October 2023, is now approved as the first new ...

Regulatory action was based on data from the Phase III QUASAR trial, which demonstrated that Eylea HD dosed every eight weeks ...

BRIDGEWATER, NJ, USA and BENGALURU, Karnataka, India I April 15, 2025 I Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today a settlement and license agreement with ...

When you have both ulcerative colitis (UC) and diabetes, it’s a balancing act. The two diseases can overlap and interact in frustrating ways, and sometimes treating one condition worsens ...

Longest international trial on the effects of tirzepatide on weight in 700 adults with overweight or obesity and prediabetes reveals three distinct patterns of weight loss trajectories, with patients ...

Further, CRISPR Therapeutics has a pipeline with several other exciting candidates, including a potential functional cure for type 1 diabetes and ... world's top-selling drugs Regeneron (NASDAQ ...

Further, CRISPR Therapeutics has a pipeline with several other exciting candidates, including a potential functional cure for type 1 diabetes and ... to major gains for Regeneron.

Pamalican Asset Management just snagged 6,900 shares of Regeneron Pharmaceuticals, making the biotech giant its 16th largest holding. This $4.9 million investment joins a stampede of institutional ...